Business
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Applies for FDA Commissioner's National Priority Voucher for IV Ketamine NRX-100
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 30, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage bi...
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.","length":145,"tagName":"p"},{"type":"text","content":"LOS ANGELES, CA - June 30, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and PTSD, is accelerating its push toward regulatory approval of NRX-100, a preservative-free intravenous ketamine formulation. The company has filed an application under the newly created FDA Commissioner's National Priority Voucher ("CNPV") program, which promises significantly shortened review timelines for drugs that meet urgent U.S. health priorities (https://ibn.fm/VeYud).","length":580,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The new FDA voucher program aims to speed approval of drugs aligned with national health priorities.","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"NRX-100, a preservative-free ketamine, is also under an Abbreviated New Drug Application ("ANDA") with a priority review request.","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"NRx has submitted full CMC data and draft labeling for NRX-100, meeting key Commissioner's National Priority Voucher pre-qualification criteria.","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"The company's U.S.-based manufacturing aims to reduce foreign supply chain dependence and address diversion concerns.","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"A patent on the preservative-free process and a citizen petition to withdraw preserved ketamine could bolster NRx's market position.","length":136,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":644,"olType":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"Investor Brand Network","className":"","disableSlideshowImg":false,"size":{"original":{"width":1400,"height":800,"url":"https://media.zenfs.com/en/newsmediawire_165/176e8941c94808aff9c938d472630a9d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/f0t0bTfV_CQY6oMk1_54vg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0OTtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/176e8941c94808aff9c938d472630a9d","width":96...